NEW YORK – DnaNudge said on Wednesday that it has inked a deal with DAM Health to distribute its COVID-19 PCR test across more than 100 clinics in the UK and globally in 2022.
The RT-PCR point-of-care test will initially be available in clinics in Liverpool, Manchester, and Wirral in the UK, DnaNudge said in a statement. In early 2022, its availability will be expanded to the entire DAM Health estate, which includes clinics in the UK, Mexico, and Spain.
The firm's CovidNudge test returns results in less than 90 minutes without requiring manual sample pre-processing. It contains a human RNAseP sample quality control to help avoid false negatives, the company said.
The test runs on the DnaCartridge, a disposable lab-on-a-chip device that doesn't require transport medium or pipetting, and the NudgeBox, a standalone RT-PCR instrument. The cartridge can multiplex up to 72 assays and detects every published COVID-19 gene and all known variants, including Omicron, the company said.
London-based DnaNudge, a spinout from Imperial College London, recently nabbed CE marking for its multiplex respiratory panel, which detects influenza A/B, SARS-CoV-2, and respiratory syncytial virus.